search
Back to results

An Open-Label Trial of Aripiprazole in Children and Adolescents With Bipolar Disorder

Primary Purpose

Bipolar Disorder

Status
Completed
Phase
Phase 3
Locations
Study Type
Interventional
Intervention
Aripiprazole
Sponsored by
University of Cincinnati
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Bipolar Disorder focused on measuring child, adolescent

Eligibility Criteria

7 Years - 18 Years (Child, Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Male or Females; between the ages of 7 years 0 months to 17 years 12 months Bipolar I Disorder, mixed or manic episode, psychotic or non-psychotic, according to DSM IV criteria. Score of > 20 on the Y-MRS at baseline. Ability and willingness to provide assent and informed written consent from at least one parent or legal guardian No current general medical illnesses requiring medication that would effect interpretation of study outcomes. Subjects must have at least normal intelligence. Female patients of childbearing potential must be using a reliable method of contraception, e.g. hormonal contraceptives, Depo-Provera, double-barrier methods (e.g. condom and diaphragm, condom and foam, condom and sponge) or abstinence). Females of childbearing potential must have a negative serum pregnancy test immediately prior to study entry. Must be able to swallow oral medication (tablets). Exclusion Criteria: A current or lifetime DSM-IV diagnosis of schizophrenia, autistic disorder, schizoaffective disorder, pervasive developmental disorder, or obsessive compulsive disorder Known IQ < 70 Patients with high suicide risk defined as any serious suicide attempt that required medical intervention or current suicide risk that cannot be safely managed as determined by the clinical judgment of the investigator. Concurrent cognitive behavioral psychotherapy. Present or past (within 3 months) DSM-IV diagnosis of substance abuse/dependence. Female patients who are pregnant, trying to become pregnant, nursing an infant, or not using a reliable form of contraception. Bipolar subjects who are currently stable on mood stabilizers or atypical neuroleptics. Patient has failed on a previous adequate course of aripiprazole. A known hypersensitivity to aripiprazole or to any of its components. Participated in an investigational drug/device trial within the last 30 days. Patients with severe renal insufficiency, defined as creatinine clearance <30ml/min. by history or by lab findings. -

Sites / Locations

    Outcomes

    Primary Outcome Measures

    YMRS & CGI

    Secondary Outcome Measures

    OAS CDRS-R

    Full Information

    First Posted
    September 14, 2005
    Last Updated
    June 26, 2013
    Sponsor
    University of Cincinnati
    Collaborators
    Children's Hospital Medical Center, Cincinnati, Bristol-Myers Squibb
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT00221416
    Brief Title
    An Open-Label Trial of Aripiprazole in Children and Adolescents With Bipolar Disorder
    Official Title
    An Open-Label Trial of Aripiprazole in Children and Adolescents With Bipolar Disorder
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    June 2013
    Overall Recruitment Status
    Completed
    Study Start Date
    June 2005 (undefined)
    Primary Completion Date
    October 2008 (Actual)
    Study Completion Date
    December 2008 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    University of Cincinnati
    Collaborators
    Children's Hospital Medical Center, Cincinnati, Bristol-Myers Squibb

    4. Oversight

    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    This is an investigator-initiated study whose primary aim is to determine the effectiveness of aripiprazole (Abilify®) in helping persons with symptoms of mania whose current medications do not completely control those symptoms. Aripiprazole is a medication that has been approved by the United States Food and Drug Administration (FDA) for the treatment of Schizophrenia. A secondary aim of this research is to explore whether CYP 2D6 polymorphisms are related to side effects with aripiprazole. The goal of this research is to identify individuals who metabolize aripiprazole more rapidly or slowly, which will potentially help the clinician make dosing adjustments and decrease the risk of adverse events.
    Detailed Description
    The primary aim of this study is to assess the effectiveness, safety, and tolerability of aripiprazole for the treatment of children and adolescents with bipolar disorder. The secondary aim of this study is to determine if common polymorphic variations in the CYP 2D6 gene underlie the inter-individual variability in aripiprazole systemic drug exposure and the occurrence of treatment emergent side effects.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Bipolar Disorder
    Keywords
    child, adolescent

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 3
    Interventional Study Model
    Single Group Assignment
    Masking
    None (Open Label)
    Allocation
    Non-Randomized
    Enrollment
    30 (Anticipated)

    8. Arms, Groups, and Interventions

    Intervention Type
    Drug
    Intervention Name(s)
    Aripiprazole
    Intervention Description
    5-20 mg/day
    Primary Outcome Measure Information:
    Title
    YMRS & CGI
    Time Frame
    6 weeks
    Secondary Outcome Measure Information:
    Title
    OAS CDRS-R
    Time Frame
    6 weeks

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    7 Years
    Maximum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Male or Females; between the ages of 7 years 0 months to 17 years 12 months Bipolar I Disorder, mixed or manic episode, psychotic or non-psychotic, according to DSM IV criteria. Score of > 20 on the Y-MRS at baseline. Ability and willingness to provide assent and informed written consent from at least one parent or legal guardian No current general medical illnesses requiring medication that would effect interpretation of study outcomes. Subjects must have at least normal intelligence. Female patients of childbearing potential must be using a reliable method of contraception, e.g. hormonal contraceptives, Depo-Provera, double-barrier methods (e.g. condom and diaphragm, condom and foam, condom and sponge) or abstinence). Females of childbearing potential must have a negative serum pregnancy test immediately prior to study entry. Must be able to swallow oral medication (tablets). Exclusion Criteria: A current or lifetime DSM-IV diagnosis of schizophrenia, autistic disorder, schizoaffective disorder, pervasive developmental disorder, or obsessive compulsive disorder Known IQ < 70 Patients with high suicide risk defined as any serious suicide attempt that required medical intervention or current suicide risk that cannot be safely managed as determined by the clinical judgment of the investigator. Concurrent cognitive behavioral psychotherapy. Present or past (within 3 months) DSM-IV diagnosis of substance abuse/dependence. Female patients who are pregnant, trying to become pregnant, nursing an infant, or not using a reliable form of contraception. Bipolar subjects who are currently stable on mood stabilizers or atypical neuroleptics. Patient has failed on a previous adequate course of aripiprazole. A known hypersensitivity to aripiprazole or to any of its components. Participated in an investigational drug/device trial within the last 30 days. Patients with severe renal insufficiency, defined as creatinine clearance <30ml/min. by history or by lab findings. -
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Robert A Kowatch, MD
    Organizational Affiliation
    University of Cincinnati
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Learn more about this trial

    An Open-Label Trial of Aripiprazole in Children and Adolescents With Bipolar Disorder

    We'll reach out to this number within 24 hrs